Physician profile
Mariam Amin
NPI 1588027981
$6,075.48
in general payments reported to CMS, 2019-2025
26 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $688 · 2023: $1,029 · 2024: $3,049 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,133.95 |
| Education | $111.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.95 | 2021-2025 | Rinvoq, Skyrizi, Botox |
| Regeneron Healthcare Solutions, INC. | $798.86 | 2021-2025 | Dupixent |
| Incyte Corporation | $585.32 | 2022-2025 | Opzelura |
| Genzyme Corporation | $578.13 | 2022-2024 | |
| Lilly USA, LLC | $470.29 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $380.63 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $325.73 | 2024-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $209.97 | 2023-2024 | |
| Amgen INC. | $187.91 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $182.11 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $163.21 | 2024-2025 | Sotyktu |
| Dermavant Sciences, INC. | $158.23 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $143.45 | 2024-2025 | |
| Galderma Laboratories, L.P. | $119.14 | 2024-2025 | Nemluvio, Dysport |
| Allergan, INC. | $113.69 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $110.46 | 2024-2025 | Adbry |
| Ucb, INC. | $109.18 | 2024-2025 | Bimzelx |
| Organon LLC | $78.54 | 2025 | Vtama |
| Almirall LLC | $53.47 | 2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.68 | 2024 | Spevigo |
| Revance Therapeutics, INC. | $48.71 | 2024-2025 | Daxi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.12 | 2024 | Cabtreo, Jublia, Arazlo |
| Biofrontera INC. | $43.64 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Strata Skin Sciences, INC. | $42.74 | 2022-2023 | Xtrac |
| Journey Medical Corporation | $21.79 | 2023 | |
| Botanix Sb INC | $13.53 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.